AB5636P
Anti-Cannabinoid Receptor 1 Antibody, NT
Chemicon®, from rabbit
Sinônimo(s):
CB1
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Produtos recomendados
fonte biológica
rabbit
Nível de qualidade
forma do anticorpo
affinity purified immunoglobulin
tipo de produto de anticorpo
primary antibodies
clone
polyclonal
purificado por
affinity chromatography
reatividade de espécies
human, rat, mouse
fabricante/nome comercial
Chemicon®
técnica(s)
ELISA: suitable
western blot: suitable
nº de adesão NCBI
nº de adesão UniProt
Condições de expedição
dry ice
modificação pós-traducional do alvo
unmodified
Informações sobre genes
human ... CNR1(1268)
mouse ... Cnr1(12801)
Especificidade
Recognizes human Cannabinoid Receptor 1 (CB1). The immunogen shows no significant sequence homology with CB2 or other receptors.
Imunogênio
A 14 amino acid N-terminus peptide sequence (aa 1-14) (Gerard et al. 1991; Gerard et al.
1990; Shire et al. 1995; Matsuda et al. 1990; Ho et al. 1996; Chakraborty et al. 1995).
1990; Shire et al. 1995; Matsuda et al. 1990; Ho et al. 1996; Chakraborty et al. 1995).
Epitope: N-terminus
Aplicação
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neuroinflammation & Pain
Neurotransmitters & Receptors
Neuroinflammation & Pain
Neurotransmitters & Receptors
This Anti-Cannabinoid Receptor 1 Antibody, N-terminus is validated for use in ELISA, WB for the detection of Cannabinoid Receptor 1.
Western blot: 1-10 μg/mL using ECL. Expected sizes are ~60kDa and 80-84kDa under reducing conditions.
ELISA: 1:10,000-1:100,000 using 50-100 ng control peptide (Cat. No. AG357) per well.
Optimal working dilutions must be determined by the end user.
ELISA: 1:10,000-1:100,000 using 50-100 ng control peptide (Cat. No. AG357) per well.
Optimal working dilutions must be determined by the end user.
Descrição-alvo
~60kDa and 80-84kDa
forma física
Affinity Purified immunoglobulin. Liquid in 100mM Tris, pH 7.5, containing 0.2% BSA and 0.05% sodium azide.
ImmunoAffinity Purified
Armazenamento e estabilidade
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Nota de análise
Control
Brain tissue
Brain tissue
Outras notas
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informações legais
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Exoneração de responsabilidade
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Não está encontrando o produto certo?
Experimente o nosso Ferramenta de seleção de produtos.
Código de classe de armazenamento
12 - Non Combustible Liquids
Classe de risco de água (WGK)
WGK 2
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Certificados de análise (COA)
Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor.
Hebert-Chatelain, E; Reguero, L; Puente, N; Lutz, B; Chaouloff, F; Rossignol, R; Piazza et al.
Molecular Metabolism null
C Song et al.
Life sciences, 56(23-24), 1983-1989 (1995-01-01)
To study the N-linked glycosylation properties of the CB1 receptor, rat brain membranes were treated with exo- and endoglycosidases. For visualizing CB1 receptors, an antipeptide antibody was raised against the N-terminal 14 amino acids and used to specifically detect the
Andrew P Ray et al.
Behavioural brain research, 196(1), 30-36 (2008-08-30)
Cisplatin chemotherapy frequently causes severe vomiting in two temporally separated clusters of bouts dubbed the acute and delayed phases. Cannabinoids can inhibit the acute phase, albeit through a poorly understood mechanism. We examined the substrates of cannabinoid-mediated inhibition of both
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica